TrialsgrambetaRCTs are beautiful

PACIFIC

2017

Durvalumab Consolidation after Chemoradiotherapy in Stage III NSCLC

In 713 patients with unresectable stage III NSCLC and no progression after concurrent chemoradiation, durvalumab consolidation for one year improved progression-free and overall survival compared with placebo.

Result

Efficacy: PFS and OS (co-primary)HR 0.52

Below 1 favours durvalumab consolidation for one year, above 1 favours placebo.

Event rates Durvalumab consolidation for one year 16.8 vs placebo 5.6 months

Also reported: 5-yr OS 42.9% vs 33.4%; 5-yr PFS 33.1% vs 19.0%.

Original publication
Subtopic
Stage III NSCLC
Design
Double-blind RCT, 2:1 randomisation
Relevance
Important: one of several pillars.
Source
Antonia SJ, et al. N Engl J Med. 2017;377(20):1919-1929; Spigel DR, et al. J Clin Oncol. 2022;40(12):1301-1311.doi 10.1056/NEJMoa1709937

Discussion & critique

Established the 'PACIFIC regimen' as global standard for unresectable stage III NSCLC. Excluded EGFR-mutated disease; separate evidence applies there.